Max Healthcare Institute (543220) Q4 16/17 earnings summary

Executive summary

• FY17 revenue and cash profits improved as operations strengthened, acquired hospitals were integrated and offerings expanded; late-year stent price regulation weighed on revenue and profitability.

• Consolidated results moved to profit, while standalone results remained loss-making; bed occupancy held up despite capacity growth.

Financial highlights

• Consolidated revenue from operations was ₹162,675 lakh vs ₹143,413 lakh in FY16; total income was ₹167,811 lakh vs ₹147,054 lakh.

• Consolidated profit after tax was ₹905 lakh vs a loss of ₹2,261 lakh; basic EPS was ₹0.18 vs loss per share of ₹0.36.

• Standalone revenue from operations was ₹98,425 lakh vs ₹91,238 lakh; loss after tax narrowed to ₹1,275 lakh from ₹2,355 lakh.

• Standalone cash profit was ₹38 crore, up 40.7% YoY; net loss was ₹14 crore vs ₹24 crore in FY16.

Outlook and guidance

• Management expected the proposed Max Medical Services merger to support a return to profits; productivity, cost optimization and operating-efficiency initiatives were expected to improve profitability.

• Priorities included higher occupancy, shorter inpatient stays, improved patient safety and discharge efficiency, and a specialty mix weighted toward complex, higher-realization procedures.

• Growth plans focused on strengthening existing hospitals, expanding bed capacity and upgrading clinical talent, medical technology and infrastructure.